|
de Alboran, I M; O'Hagan, R C; Gartner, F et al. (2001) Analysis of C-MYC function in normal cells via conditional gene-targeted mutation. Immunity 14:45-55
|
|
O'Hagan, R C; Schreiber-Agus, N; Chen, K et al. (2000) Gene-target recognition among members of the myc superfamily and implications for oncogenesis. Nat Genet 24:113-9
|
|
Bardeesy, N; Wong, K K; DePinho, R A et al. (2000) Animal models of melanoma: recent advances and future prospects. Adv Cancer Res 79:123-56
|
|
Malynn, B A; de Alboran, I M; O'Hagan, R C et al. (2000) N-myc can functionally replace c-myc in murine development, cellular growth, and differentiation. Genes Dev 14:1390-9
|
|
Shen-Li, H; O'Hagan, R C; Hou Jr, H et al. (2000) Essential role for Max in early embryonic growth and development. Genes Dev 14:17-22
|
|
Gomez Lahoz, E; Liegeois, N J; Zhang, P et al. (1999) Cyclin D- and E-dependent kinases and the p57(KIP2) inhibitor: cooperative interactions in vivo. Mol Cell Biol 19:353-63
|
|
Greenberg, R A; O'Hagan, R C; Deng, H et al. (1999) Telomerase reverse transcriptase gene is a direct target of c-Myc but is not functionally equivalent in cellular transformation. Oncogene 18:1219-26
|
|
Chin, L; Pomerantz, J; DePinho, R A (1998) The INK4a/ARF tumor suppressor: one gene--two products--two pathways. Trends Biochem Sci 23:291-6
|
|
Chin, L; Merlino, G; DePinho, R A (1998) Malignant melanoma: modern black plague and genetic black box. Genes Dev 12:3467-81
|
|
Zhang, P; Wong, C; DePinho, R A et al. (1998) Cooperation between the Cdk inhibitors p27(KIP1) and p57(KIP2) in the control of tissue growth and development. Genes Dev 12:3162-7
|
Showing the most recent 10 out of 22 publications
